We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will UnitedHealth's New Optum Rx Model Boost PBM Pricing Transparency?
Read MoreHide Full Article
Key Takeaways
UnitedHealth's Optum Rx launched a transparent PBM model with fee-based pricing and full fee disclosure.
Optum Rx is eliminating spread pricing and adding tools showing real-time prescription costs and options.
Optum Rx Q1 2026 earnings fell to $1.2B as membership attrition at UHC pressured volumes.
UnitedHealth Group Incorporated’s (UNH - Free Report) pharmacy benefit management arm, Optum Rx, rolled out an industry-first transparent pharmacy care model that shifts away from opaque pricing tied to drug makers’ list prices and prescription volume to a clear, fee-based structure for all its PBM clients. The plan discloses every fee, eliminates spread pricing and adds digital tools that show patients real-time costs and options before they fill a prescription, aiming for simpler, predictable pharmacy benefits.
This move tackles long-standing opacity in drug pricing that frustrates patients and employers, promising clearer costs and better control over pharmacy spend in a system under regulatory scrutiny. In today’s political climate, where lawmakers are pushing PBM transparency and drug cost reforms, UnitedHealth’s move positions it as proactive, potentially easing regulatory pressure and aligning with broader cost-reduction goals.
Financially, the new model could stabilize and grow PBM margins by reducing unpredictable spreads and strengthening client trust, potentially attracting more contracts. Optum Rx, one of the nation’s largest PBMs, saw an adjusted operating margin of 3.3% in the first quarter of 2026, down from 3.8% a year ago.
Clear pricing and consumer tools may also reduce churn and lower cost trends, supporting long-term revenue sustainability. In the first quarter of 2026, Optum Rx posted earnings of $1.2 billion, down from $1.3 billion a year ago, pressured by lower volumes tied to membership attrition at UHC. Still, Optum remains a key stabilizer for UnitedHealth as its insurance arm wrestles with elevated medical costs.
Peers Suffering From Rising Medical Costs Trend Too
UnitedHealth’s peers, including Centene Corporation (CNC - Free Report) and Elevance Health, Inc. (ELV - Free Report) , are also grappling with rising medical costs due to higher utilization trends. Nevertheless, the companies are managing the problem better now.
Centene witnessed its health benefits ratio decrease to 87.3% in the first quarter from 87.5% a year ago, thanks to rate and revenue increases, improving medical cost management and moderate flu costs. Meanwhile, Elevance Health’s benefit expense ratio increased to 86.8% from 86.4% a year ago, due to higher medical costs, partially offset by improved Medicare performance.
UnitedHealth’s Price Performance, Valuation and Estimates
Shares of UNH have gained 16.5% in the year-to-date period compared with the industry’s growth of 14.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 20.15, up from the industry average of 16.95. UNH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $18.25 per share, implying an 11.6% improvement from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Will UnitedHealth's New Optum Rx Model Boost PBM Pricing Transparency?
Key Takeaways
UnitedHealth Group Incorporated’s (UNH - Free Report) pharmacy benefit management arm, Optum Rx, rolled out an industry-first transparent pharmacy care model that shifts away from opaque pricing tied to drug makers’ list prices and prescription volume to a clear, fee-based structure for all its PBM clients. The plan discloses every fee, eliminates spread pricing and adds digital tools that show patients real-time costs and options before they fill a prescription, aiming for simpler, predictable pharmacy benefits.
This move tackles long-standing opacity in drug pricing that frustrates patients and employers, promising clearer costs and better control over pharmacy spend in a system under regulatory scrutiny. In today’s political climate, where lawmakers are pushing PBM transparency and drug cost reforms, UnitedHealth’s move positions it as proactive, potentially easing regulatory pressure and aligning with broader cost-reduction goals.
Financially, the new model could stabilize and grow PBM margins by reducing unpredictable spreads and strengthening client trust, potentially attracting more contracts. Optum Rx, one of the nation’s largest PBMs, saw an adjusted operating margin of 3.3% in the first quarter of 2026, down from 3.8% a year ago.
Clear pricing and consumer tools may also reduce churn and lower cost trends, supporting long-term revenue sustainability. In the first quarter of 2026, Optum Rx posted earnings of $1.2 billion, down from $1.3 billion a year ago, pressured by lower volumes tied to membership attrition at UHC. Still, Optum remains a key stabilizer for UnitedHealth as its insurance arm wrestles with elevated medical costs.
Peers Suffering From Rising Medical Costs Trend Too
UnitedHealth’s peers, including Centene Corporation (CNC - Free Report) and Elevance Health, Inc. (ELV - Free Report) , are also grappling with rising medical costs due to higher utilization trends. Nevertheless, the companies are managing the problem better now.
Centene witnessed its health benefits ratio decrease to 87.3% in the first quarter from 87.5% a year ago, thanks to rate and revenue increases, improving medical cost management and moderate flu costs. Meanwhile, Elevance Health’s benefit expense ratio increased to 86.8% from 86.4% a year ago, due to higher medical costs, partially offset by improved Medicare performance.
UnitedHealth’s Price Performance, Valuation and Estimates
Shares of UNH have gained 16.5% in the year-to-date period compared with the industry’s growth of 14.7%.
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 20.15, up from the industry average of 16.95. UNH carries a Value Score of B.
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $18.25 per share, implying an 11.6% improvement from the year-ago period.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.